) The goal of the Antigen and Antibody Production Shared Resource is to provide timely services to investigators that include: 1. GST-fusion protein production. 2. Mouse polyclonal antisera production. 3. Mouse monoclonal antibody. 4. Single cell cloning and cryopreservation of the subclone. 5. The use of above reagents in characterizing specific gene products. Genes important for cancer predisposition, progression, and prognosis are being identified at a remarkable pace. Accompanying these findings is the identification of their interacting proteins that are important for the gene function. Discoveries of BRCA1 and BRCA2, and subsequently, demonstration of their interaction with the DNA repair proteins, Rad51 and Rad50, have highlighted such discoveries in breast cancer studies. The timely development of purified fusion proteins facilitates studies of gene function and production of antibodies are required for the identification of specific gene products, immunostaining to localize the protein, screening gene mutation in cancer samples, and studies of interacting proteins. This core will provide a streamlined service once a cDNA fragment with open reading frame is obtained. Since GST-fusion proteins usually serve as excellent antigens, we will use purified GST-fusion proteins as antigens to produce polyclonal and monoclonal antibodies. High quality polyclonal antibodies, suitable for immunoprecipitation, immunoblotting and immunostaining, will be produced in mice house in the pathogen-free facility. A well-established hybridoma core facility will provide services on monoclonal antibody products. The core will also provide advice on approaches and services for protein product identification and localization of protein product, immunostaining, and image analysis of cell lines or tissue sections stained with a specific antibody. Since studies or protein products of newly identified tumor suppressor genes, signaling molecules, and their interacting molecules have important prognostic and diagnostic potential, providing well-characterized antibodies in a timely manner will meet the special needs of the SACI investigators.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA054174-09
Application #
6203206
Study Section
Project Start
1999-08-01
Project End
2000-07-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
9
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Ctrc Research Foundation
Department
Type
DUNS #
City
San Antonio
State
TX
Country
United States
Zip Code
78229
Abbott, Jamie A; Meyer-Schuman, Rebecca; Lupo, Vincenzo et al. (2018) Substrate interaction defects in histidyl-tRNA synthetase linked to dominant axonal peripheral neuropathy. Hum Mutat 39:415-432
Guo, Jiayan; Kim, Hong Seok; Asmis, Reto et al. (2018) Interactions of ? tubulin isotypes with glutathione in differentiated neuroblastoma cells subject to oxidative stress. Cytoskeleton (Hoboken) 75:283-289
Liss, Michael A; Chen, Yidong; Rodriguez, Ronald et al. (2018) Immunogenic Heterogeneity of Renal Cell Carcinoma With Venous Tumor Thrombus. Urology :
Zhu, Haiyan; Xia, Lu; Shen, Qi et al. (2018) Differential effects of GLI2 and GLI3 in regulating cervical cancer malignancy in vitro and in vivo. Lab Invest 98:1384-1396
Zeno, Wade F; Baul, Upayan; Snead, Wilton T et al. (2018) Synergy between intrinsically disordered domains and structured proteins amplifies membrane curvature sensing. Nat Commun 9:4152
Mahalingam, Devalingam; Goel, Sanjay; Aparo, Santiago et al. (2018) A Phase II Study of Pelareorep (REOLYSIN®) in Combination with Gemcitabine for Patients with Advanced Pancreatic Adenocarcinoma. Cancers (Basel) 10:
Yu, Xiaojie; Zhang, Yiqiang; Ma, Xiuye et al. (2018) miR-195 potentiates the efficacy of microtubule-targeting agents in non-small cell lung cancer. Cancer Lett 427:85-93
Ankerst, Donna P; Goros, Martin; Tomlins, Scott A et al. (2018) Incorporation of Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG into Prostate Cancer Prevention Trial Risk Calculator. Eur Urol Focus :
Arora, Sukeshi Patel; Mahalingam, Devalingam (2018) Immunotherapy in colorectal cancer: for the select few or all? J Gastrointest Oncol 9:170-179
Arellano, Luisa M; Arora, Sukeshi Patel (2018) Systemic Treatment of Advanced Hepatocellular Carcinoma in Older Adults. J Nat Sci 4:

Showing the most recent 10 out of 989 publications